Specific copy number alterations associated with docetaxel/carboplatin response in ovarian carcinomas.

BACKGROUND The continued high recurrence and mortality rate in ovarian cancer is a significant problem and the major obstacle in the treatment of ovarian cancer patients is chemotherapy resistance. Thus, finding predictive markers of chemoresistance and elucidating resistance mechanisms is crucial for individualising treatment and improving survival of ovarian cancer patients. MATERIALS AND METHODS Using array comparative genomic hybridisation (CGH), this pilot study analysed the tumour genomes of patients treated with docetaxel/carboplatin as first-line chemotherapy (6 resistant versus 24 sensitive cases). This is the first array CGH study of such material. RESULTS The study identified genetic alterations specific to chemoresistant (gains in 9p13.2-13.1, 9q21.2-21.32, 9q21.33, 9q22.2-22.31, 9q22.32-22.33 and 9q33.1-34.11) and chemosensitive (losses in 8p23.3-23.1 and 8p22) disease. Additionally, when comparing the results to previously analysed tumour material from patients treated with paclitaxel/carboplatin, the two datasets identified different genetic alteration profiles. CONCLUSION Specific genetic alterations were identified and associated with chemotherapy response in ovarian cancer. It will be interesting to investigate these exciting data further in larger independent series of ovarian tumours, and hopefully will contribute to the establishment of predictive markers.

[1]  Björn Olsson,et al.  Potential predictive markers of chemotherapy resistance in stage III ovarian serous carcinomas , 2009, BMC Cancer.

[2]  S. Minkin,et al.  High-resolution mapping of genomic imbalance and identification of gene expression profiles associated with differential chemotherapy response in serous epithelial ovarian cancer. , 2005, Neoplasia.

[3]  N. Haites,et al.  Genomic changes identified by comparative genomic hybridisation in docetaxel-resistant breast cancer cell lines. , 2005, European journal of cancer.

[4]  B. M. Forman,et al.  The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux , 2001, Nature Medicine.

[5]  K. Helou,et al.  Analysis of cytogenetic alterations in stage III serous ovarian adenocarcinoma reveals a heterogeneous group regarding survival, surgical outcome, and substage , 2004, Genes, chromosomes & cancer.

[6]  Kenneth H. Downing,et al.  Structure of the αβ tubulin dimer by electron crystallography , 1998, Nature.

[7]  V. Diéras,et al.  The taxanes: toxicity and quality of life considerations in advanced ovarian cancer , 2003, British Journal of Cancer.

[8]  L. Aaltonen,et al.  Comparison of Serous and Mucinous Ovarian Carcinomas: Distinct Pattern of Allelic Loss at Distal 8p and Expression of Transcription Factor GATA-4 , 2001, Laboratory Investigation.

[9]  C. Hennequin,et al.  S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells. , 1995, British Journal of Cancer.

[10]  Taisuke Mori,et al.  A pilot study of docetaxel-carboplatin versus paclitaxel-carboplatin in Japanese patients with epithelial ovarian cancer , 2007, International Journal of Clinical Oncology.

[11]  B. Olsson,et al.  Chromosomal changes associated with clinical outcome in lymph node-negative breast cancer. , 2007, Cancer genetics and cytogenetics.

[12]  Jane Fridlyand,et al.  Bioinformatics Original Paper a Comparison Study: Applying Segmentation to Array Cgh Data for Downstream Analyses , 2022 .

[13]  N. Katsumata.  Docetaxel: an alternative taxane in ovarian cancer , 2003, British Journal of Cancer.

[14]  S. Gruvberger,et al.  BioArray Software Environment (BASE): a platform for comprehensive management and analysis of microarray data , 2002, Genome Biology.

[15]  Y. Shi,et al.  Characterization of the gene encoding pinin/DRS/memA and evidence for its potential tumor suppressor function , 2000, Oncogene.

[16]  G. Hortobagyi,et al.  A phase II study of docetaxel in patients with paclitaxel-resistant metastatic breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  S. Kaye,et al.  Docetaxel in the management of ovarian cancer , 2005, Expert review of anticancer therapy.

[18]  Hys Ngan,et al.  Carcinoma of the Ovary , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[19]  K. Helou,et al.  Cytogenetic analysis of carboplatin resistance in early-stage epithelial ovarian carcinoma. , 2005, Cancer genetics and cytogenetics.

[20]  Alan Gordon,et al.  Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. , 2004, Journal of the National Cancer Institute.

[21]  I. Ringel,et al.  Studies with RP 56976 (taxotere): a semisynthetic analogue of taxol. , 1991, Journal of the National Cancer Institute.

[22]  D. Birnbaum,et al.  High frequency of allelic imbalance at regions of chromosome arm 8p in ovarian carcinoma. , 2001, Cancer genetics and cytogenetics.

[23]  R. Uppaluri,et al.  Transcript map of the 8p23 putative tumor suppressor region. , 2001, Genomics.

[24]  M. Untch,et al.  Comparison of paclitaxel and docetaxel (Taxotere) in gynecologic and breast cancer cell lines with the ATP-cell viability assay. , 1994, Anti-cancer drugs.

[25]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[26]  P. Rose,et al.  A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. , 2003, Gynecologic oncology.

[27]  G. Chenevix-Trench,et al.  Frequent loss of heterozygosity and three critical regions on the short arm of chromosome 8 in ovarian adenocarcinomas , 1998, Oncogene.

[28]  M. Marty,et al.  Phase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusion. , 1993, Cancer research.

[29]  J. Gligorov,et al.  Preclinical pharmacology of the taxanes: implications of the differences. , 2004, The oncologist.

[30]  E. Atkinson,et al.  Docetaxel for patients with paclitaxel-resistant Müllerian carcinoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  M. Kiechle,et al.  Comparative genomic hybridization detects genetic imbalances in primary ovarian carcinomas as correlated with grade of differentiation , 2001, Cancer.

[32]  Jae Hoon Kim,et al.  Analysis of chromosomal changes in serous ovarian carcinoma using high‐resolution array comparative genomic hybridization: Potential predictive markers of chemoresistant disease , 2007, Genes, chromosomes & cancer.

[33]  A. Tsalenko,et al.  High definition cytogenetics and oligonucleotide aCGH analyses of cisplatin‐resistant ovarian cancer cells , 2007, Genes, chromosomes & cancer.

[34]  B. Ramaswamy,et al.  Docetaxel: a tubulin-stabilizing agent approved for the management of several solid tumors. , 2006, Drugs of today.

[35]  A. Godwin,et al.  Comparative genomic hybridization detects frequent overrepresentation of chromosomal material from 3q26, 8q24, and 20q13 in human ovarian carcinomas , 1997, Genes, chromosomes & cancer.

[36]  Jaakko Astola,et al.  CGH-Plotter: MATLAB toolbox for CGH-data analysis , 2003, Bioinform..

[37]  Hanna Göransson,et al.  Screening for copy‐number alterations and loss of heterozygosity in chronic lymphocytic leukemia—A comparative study of four differently designed, high resolution microarray platforms , 2008, Genes, chromosomes & cancer.

[38]  S. Sugrue,et al.  Characterization of pinin, a novel protein associated with the desmosome-intermediate filament complex , 1996, The Journal of cell biology.

[39]  Johan Staaf,et al.  Normalization of array-CGH data: influence of copy number imbalances , 2007, BMC Genomics.